Developer docs
API playgroundTry for free, no card

Search company profiles

Neuralocity

Full company profile

uuid000yd2m

Namestring
Neuralocity
Legal namestring
Neuralocity LLC
Websiteurl
neuralocity.com
Company typeenum
Private
Founded yearint
2016
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersChandler, United States
HQ citystring
Chandler
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
AI drug discovery, machine learning consulting, predictive analytics, data visualization services, computational biology
Industry1 code
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Research and Development in the Physical, Engineering, and Life Sciences54171
SIC code1 code
  • Services-Prepackaged Software7372
Product category
AI Drug Discovery
Social media profiles1 record
Cost components3 values
Personnel, Technology or R&D, Operations
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Neuralocity is a deep technology company that develops artificial intelligence applied to experimental drug discovery. Its offer spans machine learning, software consulting, predictive analytics, and data visualization services, targeting challenges in pharmaceutical and biotech R&D. The firm currently operates in stealth mode and has not publicly disclosed named products, pricing, or customer engagements.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Neuralocity is a deep technology company operating in stealth mode, working at the intersection of artificial intelligence and experimental drug discovery. The company has not publicly disclosed specific products, modules, or named offerings.

Product and service4 records
1Artificial Intelligence for Experimental Drug Discovery
CategoryAI Drug Discovery
Description

Application of artificial intelligence to challenges in experimental drug discovery, intended for pharmaceutical and biotechnology R&D organizations.

2Machine Learning Consulting
CategoryConsulting Services
Description

Software consulting services involving machine learning development and deployment for clients in scientific and research domains.

3Predictive Analytics Services
CategoryAnalytics Services
Description

Development and delivery of predictive analytics capabilities for clients working with experimental and scientific datasets.

4Data Visualization Services
CategoryAnalytics Services
Description

Data visualization services that translate experimental and analytical outputs into visual formats for research and business stakeholders.

Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Peers10 records
TypeDirect peer
Description

XtalPi combines AI, quantum physics, and large-scale experimental data for drug discovery and materials science. It is a direct peer in applying AI to experimental drug discovery workflows and partnering with major pharma on discovery programs.

2Isomorphic Labs
TypeBroad incumbent
Description

Isomorphic Labs is Alphabet's drug-discovery AI subsidiary, applying deep learning to molecular design and partnering with pharma majors (Novartis, Lilly). It is a broad incumbent peer with significantly more capital and compute, competing for the same AI-drug-discovery partnership value pool.

TypeDirect peer
Description

Exscientia builds AI-designed drug candidates with end-to-end discovery capabilities and has publicly disclosed pharma partnerships. It is a direct competitor in the AI-driven experimental drug discovery space, with a comparable end-customer profile of large pharmaceutical companies.

TypeBroad incumbent
Description

Schrödinger provides physics-based computational chemistry and AI-augmented drug-design software used across pharma R&D. It is a broad incumbent peer that overlaps with Neuralocity on the AI/computational side of drug discovery, though its core platform is more established and commercially deployed.

TypeDirect peer
Description

Insitro applies machine learning to predictive modeling in drug discovery, combining ML with high-throughput experimental biology. It is a direct peer because both companies position themselves at the intersection of AI and experimental drug discovery, the same target customer base (large pharma partners), and a comparable platform strategy.

TypeDirect peer
Description

Atomwise applies AI to small-molecule drug discovery, partnering with pharma and academic groups. It is a direct peer in target identification and hit generation through AI, comparable to Neuralocity's experimental drug discovery focus.

TypeDirect peer
Description

Recursion uses AI and high-throughput experimental biology to discover new therapeutics, with a public pipeline and large pharma partnerships. It directly competes with Neuralocity in the AI-for-experimental-drug-discovery category and serves the same large-pharma partner customer base.

TypeDirect peer
Description

BenevolentAI applies machine learning to drug discovery across multiple therapeutic areas. It is a direct peer in AI-augmented experimental drug discovery, with a comparable model of operating a centralized AI platform that targets pharma collaborations.

TypeEmerging player
Description

Owkin applies AI/ML to biomedical research and drug discovery, with a particular emphasis on multi-modal data integration. It is an emerging player with meaningful overlap to Neuralocity on AI applied to pharma and life-sciences R&D, although its portfolio spans diagnostics and clinical research as well.

TypeEmerging player
Description

Iambic (formerly Entasis-backed) builds AI-driven platforms for small-molecule drug discovery with experimental validation. It is an emerging player with direct overlap to Neuralocity's AI-for-experimental-drug-discovery positioning and serves the same pharma-partner customer profile.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Neuralocity

AI Drug Discoveryneuralocity.com

Neuralocity firmographics

Firmographics
Name
Neuralocity
Legal name
Neuralocity LLC
Website
https://neuralocity.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
1–10 employees
Ownership category
akta.pro rank

Neuralocity industry classification

Industry
Product category
AI Drug Discovery
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171)
SIC
Services-Prepackaged Software (7372)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

Keywords

  • AI drug discovery
  • Machine learning consulting
  • Predictive analytics
  • Data visualization services
  • Computational biology

Where Neuralocity is headquartered

Location

Headquarters

HQ city
Chandler
HQ country
United States
HQ region
North America

Markets served

Neuralocity business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations

Neuralocity product offering

Product offering

Core offering

Neuralocity is a deep technology company that develops artificial intelligence applied to experimental drug discovery. Its offer spans machine learning, software consulting, predictive analytics, and data visualization services, targeting challenges in pharmaceutical and biotech R&D. The firm currently operates in stealth mode and has not publicly disclosed named products, pricing, or customer engagements.

Product overview

Neuralocity is a deep technology company operating in stealth mode, working at the intersection of artificial intelligence and experimental drug discovery. The company has not publicly disclosed specific products, modules, or named offerings.

Differentiator

Problem solved

Functional benefit

Products and services

  • Artificial Intelligence for Experimental Drug Discovery Application of artificial intelligence to challenges in experimental drug discovery, intended for pharmaceutical and biotechnology R&D organizations.
  • Machine Learning Consulting Software consulting services involving machine learning development and deployment for clients in scientific and research domains.
  • Predictive Analytics Services Development and delivery of predictive analytics capabilities for clients working with experimental and scientific datasets.
  • Data Visualization Services Data visualization services that translate experimental and analytical outputs into visual formats for research and business stakeholders.

Companies that use Neuralocity

Customer profile

Ideal customer profiles1 record

Neuralocity technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Neuralocity partnerships and signals

Strategic signal

Recent moves3 records

Neuralocity competitors and assessment

Company assessment

Direct peers

  • XtalPi: XtalPi combines AI, quantum physics, and large-scale experimental data for drug discovery and materials science. It is a direct peer in applying AI to experimental drug discovery workflows and partnering with major pharma on discovery programs.
  • Exscientia: Exscientia builds AI-designed drug candidates with end-to-end discovery capabilities and has publicly disclosed pharma partnerships. It is a direct competitor in the AI-driven experimental drug discovery space, with a comparable end-customer profile of large pharmaceutical companies.
  • Insitro: Insitro applies machine learning to predictive modeling in drug discovery, combining ML with high-throughput experimental biology. It is a direct peer because both companies position themselves at the intersection of AI and experimental drug discovery, the same target customer base (large pharma partners), and a comparable platform strategy.
  • Atomwise: Atomwise applies AI to small-molecule drug discovery, partnering with pharma and academic groups. It is a direct peer in target identification and hit generation through AI, comparable to Neuralocity's experimental drug discovery focus.
  • Recursion Pharmaceuticals: Recursion uses AI and high-throughput experimental biology to discover new therapeutics, with a public pipeline and large pharma partnerships. It directly competes with Neuralocity in the AI-for-experimental-drug-discovery category and serves the same large-pharma partner customer base.
  • BenevolentAI: BenevolentAI applies machine learning to drug discovery across multiple therapeutic areas. It is a direct peer in AI-augmented experimental drug discovery, with a comparable model of operating a centralized AI platform that targets pharma collaborations.

Broad incumbents

  • Isomorphic Labs: Isomorphic Labs is Alphabet's drug-discovery AI subsidiary, applying deep learning to molecular design and partnering with pharma majors (Novartis, Lilly). It is a broad incumbent peer with significantly more capital and compute, competing for the same AI-drug-discovery partnership value pool.
  • Schrödinger: Schrödinger provides physics-based computational chemistry and AI-augmented drug-design software used across pharma R&D. It is a broad incumbent peer that overlaps with Neuralocity on the AI/computational side of drug discovery, though its core platform is more established and commercially deployed.

Emerging players

  • Owkin: Owkin applies AI/ML to biomedical research and drug discovery, with a particular emphasis on multi-modal data integration. It is an emerging player with meaningful overlap to Neuralocity on AI applied to pharma and life-sciences R&D, although its portfolio spans diagnostics and clinical research as well.
  • Iambic: Iambic (formerly Entasis-backed) builds AI-driven platforms for small-molecule drug discovery with experimental validation. It is an emerging player with direct overlap to Neuralocity's AI-for-experimental-drug-discovery positioning and serves the same pharma-partner customer profile.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks6 records

Key highlights5 records

Customer concentration

Neuralocity social profiles

Digital presence

Neuralocity financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Neuralocity leadership team

Management profile

Number of profiles

Profiles2 records

Neuralocity funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Neuralocity M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Neuralocity

What does Neuralocity do?

Neuralocity is a deep technology company that develops artificial intelligence applied to experimental drug discovery. Its offer spans machine learning, software consulting, predictive analytics, and data visualization services, targeting challenges in pharmaceutical and biotech R&D. The firm currently operates in stealth mode and has not publicly disclosed named products, pricing, or customer engagements.

Is Neuralocity a public or private company?

Neuralocity is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Neuralocity founded?

Neuralocity was founded in 2016. It employs 1 to 10 people.

Where is Neuralocity based?

Neuralocity is headquartered in Chandler, United States, in the North America region.

Who are Neuralocity's main competitors?

Direct peers on record are XtalPi, Exscientia, Insitro, Atomwise, Recursion Pharmaceuticals and BenevolentAI. Broad incumbents are Isomorphic Labs and Schrödinger. Emerging players are Owkin and Iambic.

Does Neuralocity have an API?

No public API is recorded for Neuralocity.

What industry is Neuralocity in?

Neuralocity's product category is AI Drug Discovery. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization. Its NAICS code is 541714 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales